BioNexus Gene Lab Corp: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 15, 2019 and accepted by EDGAR at May 15, 2019, 17:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-01-01 to 2019-03-31 | $28.1k | us-gaap:Revenues |
| Cost of revenue | 3 months2019-01-01 to 2019-03-31 | −$18.8k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-01-01 to 2019-03-31 | $9.3k | us-gaap:GrossProfit |
| Income tax | 3 months2019-01-01 to 2019-03-31 | −$1.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-01-01 to 2019-03-31 | −$61.5k | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | −$48.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-03-31 | $597.5k | us-gaap:Cash |
| Current assets | At period end2019-03-31 | $1.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $1.6m | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $66.2k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $129.6k | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-03-31 | $1.5m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2019-03-31 | 74,627,558 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001551163-19-000126. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.